• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Jessica Dean Named to National Law Journal's 2025 Elite Women of the Plaintiffs Bar

    5/27/25 10:07:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email

    Dean Omar Branham Shirley partner honored for holding corporate giants accountable

    Premier plaintiffs firm Dean Omar Branham Shirley, LLP, is proud to announce that partner Jessica Dean has been named to The National Law Journal's 2025 Elite Women of the Plaintiffs Bar, honoring women lawyers who have achieved exceptional results in high-stakes litigation on behalf of plaintiffs.

    "I'm truly honored by this recognition," said Ms. Dean. "I care deeply about my clients and so appreciate the nod towards my life's work."

    Ms. Dean has built a national reputation for holding powerful corporations accountable, with a primary focus in recent years on litigation against Johnson & Johnson (NYSE:JNJ). Her work has secured millions of dollars in compensation for victims and families of those who have lost loved ones.

    "I'm proud to work alongside Jessica," said firm partner Trey Branham. "This honor is well-deserved and reflects her tireless advocacy."

    Ms. Dean has secured life-changing verdicts for victims of corporate negligence and exposed systemic abuses that allow powerful entities to evade accountability. She and her firm secured several verdicts in 2024, including $45 million from a Chicago jury in the death of a mother of six, Theresa Garcia. This case, like many others, was mired in delays due to Johnson & Johnson's attempts to exploit the bankruptcy system to evade responsibility.

    Earlier this year, Ms. Dean earned national recognition from legal guide Lawdragon, which named her to its prestigious 500 Leading Lawyers in America and its 500 Leading Plaintiff Consumer Lawyers lists.

    The National Law Journal's Elite Trial Lawyers Awards honor firms and attorneys who have achieved significant results and showcased an unwavering commitment to advancing justice for their clients.

    View the other 2025 Elite Trial Lawyers honorees and finalists here.

    About Dean Omar Branham Shirley

    Dean Omar Branham Shirley, LLP, is a nationally recognized trial firm that handles cases across the country for individuals who have suffered catastrophic injuries or have died as a result of the irresponsible conduct of others. For more information, please visit http://www.dobslegal.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250527463720/en/

    Media Contact:

    BeLynn Hollers

    800-559-4534

    [email protected]

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    More analyst ratings

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care